Relative risks of adverse effects across different opioid agonist treatments—A systematic review and meta-analysis. Meyer M, Strazdins E, Guessoum A, Westenberg JN, Appenzeller-Herzog C, Cattaneo MEGV, et al.  Addicti…

A Review of the Prospective Effects of Methadone on Peripheral Neuropathic Pain in Diabetic Patients.  Poursamimi J.  ScientificWorldJournal. 2025 Mar 5;2025:8483881. doi: 10.1155/tswj/8483881. PMID: 40225355; PMCID: PMC11986196. https…

In brief: New labeling for once-monthly subcutaneous buprenorphine (Sublocade).  Med Lett Drugs Ther. 2025 Apr 14;67(1726):63-64. doi: 10.58347/tml.2025.1726e. PMID: 40254731. https://secure.medicalletter.org/TML-article-1726e

Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series.  Hayes V, Mills L, Byron G, Stubley C, Black E, Trevitt BT, Somogyi AA, Sahid A, Lintzeris N.  Drug Alcohol Depend Rep. 2025 Apr 5;15:1003…

Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages.  Gilbert MK, Daughton AR, Chilcoat HD, Laffont CM, Strafford S, DeVeaugh-Geiss AM.  J Med Internet Res. 2025 Apr…

Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial.  Lofwall MR, Nunes EV, Walsh SL, Bailey GL, Frost M, Budilovsky-Kelley NR, Banke Nordbeck E, Meyner S, Alm…